Abstract: One example embodiment is a method of treating lung carcinoma in a subject in need thereof. The method includes administering to the subject a therapeutically effective amount of an arginine reducing compound and a therapeutically effective amount of an ornithine decarboxylase (ODC) inhibitor to provide a combination therapy that has a synergistic therapeutic effect compared to an effect of the arginine reducing compound and an effect of the ODC inhibitor, in which each of the arginine reducing compound and the ODC inhibitor is administered alone.

Abstract: The present invention provides a site-directed mutated arginase and the preparation method thereof, and the use of said site-directed mutated arginase in preparing a medicament for treating an arginase-related disease. The present invention also provides a pegylated arginase and the preparation method thereof, and the use of said pegylated arginase in preparing a medicament for treating an arginase-related disease.

Abstract: The present invention provides a site-directed mutated arginase and the preparation method thereof, and the use of said site-directed mutated arginase in preparing a medicament for treating an arginase-related disease. The present invention also provides a site-directed pegylated arginase and the preparation method thereof, and the use of said pegylated arginase in preparing a medicament for treating an arginase-related disease.

Abstract: The present invention provides a site-directed mutated arginase and the preparation method thereof, and the use of said site-directed mutated arginase in preparing a medicament for treating an arginase-related disease. The present invention also provides a pegylated arginase and the preparation method thereof, and the use of said pegylated arginase in preparing a medicament for treating an arginase-related disease.

Abstract: The present invention provides an isolated and substantially purified recombinant human arginase having sufficiently high enzymatic activity and stability to maintain Adequate Arginine Depletion in a patient. The present invention also provides a pharmaceutical composition comprising the modified invention enzyme and method for treatment of diseases using the pharmaceutical composition.

Abstract: The present invention provides a method for treatment of leukemia comprising administration of arginase to a subject in need thereof. In one embodiment, the leukemia is lymphocytic or myeloid. In another embodiment, the leukemia is arsenic resistant. In a further embodiment, the arginase is pegylated recombinant human arginase. In another embodiment, the arginase can be administrated in combination with a second therapeutic agent such as Doxorubicin in the treatment of leukemia.

Abstract: A shoulder rest (50) comprises an attachment piece (60), an abutment piece (62), and a padding piece (64) and is adapted for supporting a stringed instrument (80) such as violin or viola during playing, wherein the attachment piece (60) is adapted to clip onto an end button (82) of the stringed instrument (80) such that the contact surface between the stringed instrument (80) and the shoulder rest (50) is juxtaposing a bottom block of the stringed instrument (80).

Abstract: The present invention provides an isolated and substantially purified recombinant human arginase having sufficiently high enzymatic activity and stability to maintain Adequate Arginine Depletion in a patient. The present invention also provides a pharmaceutical composition comprising the modified invention enzyme and method for treatment of diseases using the pharmaceutical composition.

Abstract: A shoulder rest (50) comprises an attachment piece (60), an abutment piece (62), and a padding piece (64) and is adapted for supporting a stringed instrument (80) such as violin or viola during playing, wherein the attachment piece (60) is adapted to clip onto an end button (82) of the stringed instrument (80) such that the contact surface between the stringed instrument (80) and the shoulder rest (50) is juxtaposing a bottom block of the stringed instrument (80).

Abstract: The present invention provides an isolated and substantially purified recombinant human arginase having sufficiently high enzymatic activity and stability to maintain Adequate Arginine Depletion in a patient. The present invention also provides a pharmaceutical composition comprising the modified invention enzyme and method for treatment of diseases using the pharmaceutical composition.

Abstract: Methods are described for using an arginine depleting agent such as arginase and derivatives thereof, which reduce physiological arginine levels, as radioprotectants to protect normal mammalian cells from DNA damage caused by ionizing radiation. Treatment can result in the protection of normal tissues in cancer patients undergoing radiotherapy and in protection from the hazardous effects of exposure to radiological dispersal devices or occupational and environmental ionizing radiation.

Abstract: The invention discloses methods for treating hepatitis with human arginase I modified by polyethylene glycol and uses of it in manufacturing of a medicament.

Abstract: The present invention provides a method for treating cancer in a human patient by reducing the physiological arginine levels to below 10 ?M in combination with administering an anti-neoplastic compound. The present invention also provides a pharmaceutical composition comprising an arginine reducing compound, such as pegylated human arginase I, and an anti-neoplastic compound, such as 5-fluorouracil, for the treatment of malignancies in a human patient.

Abstract: The present invention provides an isolated and substantially purified recombinant human arginase having sufficiently high enzymatic activity and stability to maintain Adequate Arginine Depletion in a patient. The present invention also provides a pharmaceutical composition comprising the modified invention enzyme and method for treatment of diseases using the pharmaceutical composition.

Abstract: The present invention provides an isolated and substantially purified recombinant human arginase having sufficiently high enzymatic activity and stability to maintain Adequate Arginine Depletion in a patient. The present invention also provides a pharmaceutical composition comprising the modified invention enzyme and method for treatment of diseases using the pharmaceutical composition.